Amiodarone: Difference between revisions

(link)
Line 34: Line 34:


==Adverse Reactions==
==Adverse Reactions==
*Bradycardia, hypotension
*Bradycardia
*Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
*[[Prolonged QT]]
*[[Prolonged QT]]
*[[Thyrotoxicosis]]<ref>Rosen's 8th Edition</ref>
*[[Thyrotoxicosis]]<ref>Rosen's 8th Edition</ref>

Revision as of 01:47, 2 June 2015

General

Adult Dosing

  • V-fib/pulseless V-tach
    • Loading dose = 300mg IV bolus followed by 150mg bolus prn
  • Stable V-tach or SVT
    • Loading dose = 150mg IV in 100mL D5W over 10min
      • Follow by infusion of 1mg/min x 6hr; 0.5mg/min thereafter

Pediatric Dosing

Special Populations

Indications

  • Ventricular and supraventricular arrhythmias
  • 1st line for pulseless V-tach/V-fib
  • Used for atrial arrhythmias in pts w/ decr EF

Contraindications

  • Allergy to class/drug
  • Iodine or shellfish allergy
  • Pregnancy

Adverse Reactions

  • Bradycardia
  • Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
  • Prolonged QT
  • Thyrotoxicosis[1]
    • Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
      • Iodine-induced hyperthyroidism
        • It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
      • Drug-induced destructive thyroiditis
        • More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

  • Class III - Inhibits potassium channels
    • Impairs SA and AV node conduction
    • Decreases automaticity
    • Prolongs refractory period in accessory pathways
  • Also has class I & II properties

See Also

Sources

  1. Rosen's 8th Edition